Prolonged Increases in Public-Payer Spending and Prices After Unapproved Drug Initiative Approval of Colchicine

JAMA Intern Med. 2021 Feb 1;181(2):284-287. doi: 10.1001/jamainternmed.2020.5017.

Authors

Natalie McCormick¹, Zachary S Wallace¹, Chio Yokose¹, April Jorge¹, Chana A Sacks², John Hsu³, Hyon K Choi¹

Affiliations

¹ Clinical Epidemiology Program,Division of Rheumatology, Allergy, and Immunology,Massachusetts General Hospital, Harvard Medical School, Boston.
² Division of General Internal Medicine, Massachusetts General Hospital, Harvard Medical School, Boston.
³ Department of Health Care Policy, Massachusetts General Hospital, Harvard Medical School, Boston.

Abstract

This cohort study examines national Medicaid and Medicare drug-spending data to examine colchicine prices over the period from 2008 to 2017.

MeSH terms

Cardiovascular Agents / economics*
Colchicine / economics*
Drug Approval
Drugs, Generic / economics
Humans
Medicaid
Medicare
United States
United States Food and Drug Administration

Substances

Cardiovascular Agents
Drugs, Generic
Colchicine

Grants and funding